Intellia Therapeutics (NTLA) is back in focus after the company said it will present Phase 3 HAELO trial data for lonvo-z in hereditary angioedema at the EAACI Annual Congress 2026.

The Phase 3 HAELO data update comes after a period where Intellia’s share price has shown strong short term momentum, with a year to date share price return of 49.08% and a 1 year total shareholder return of 91.76%, despite a significantly weaker 3 year and 5 year total shareholder return.

If gene editing in rare diseases interests you, this is a good moment to widen your watchlist and see what stands out in 40 healthcare AI stocks

With Intellia’s stock up sharply in the past year yet still trading at a discount to analyst targets and certain intrinsic value estimates, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 48.6% Undervalued

At $13.73, the most followed fair value narrative of $26.70 suggests a wide gap between Intellia’s current price and what those forecasts imply.

Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.

Want to understand why this fair value almost doubles the current price? The narrative leans heavily on rapid revenue expansion, sharp margin improvement, and a rich future earnings multiple. Curious how those pieces fit together and how sensitive that $26.70 figure is to the timing of profitability and trial outcomes? The full story joins those assumptions into one pricing roadmap.

Result: Fair Value of $26.70 (UNDERVALUED)

However, this upbeat story still hinges on clean safety signals in MAGNITUDE and strong payer support for expensive one time gene editing therapies, both of which could shift sentiment quickly.

Another Take: Multiples Point the Other Way

Those fair value models paint Intellia as deeply undervalued, yet its current P/S of 29x is far higher than the US Biotechs industry at 10.9x, the peer average at 16.9x, and an estimated fair ratio of just 0.1x. Is this a bargain, or is a lot already baked into the price?

Next Steps

With such mixed signals on value and expectations, this is the moment to review the data yourself and decide what stands out. To weigh both sides quickly, check the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Intellia has your attention, do not stop here. Broaden your watchlist now so you are not relying on a single story or sector.

• Target potential mispricings by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your income focus by reviewing 10 dividend fortresses that aim to pair higher yields with resilience.
• Sleep easier by checking 62 resilient stocks with low risk scores that score well on balance sheet strength and volatility control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.